STOCK TITAN

Crinetics Pharmaceuticals Inc - CRNX STOCK NEWS

Welcome to our dedicated news page for Crinetics Pharmaceuticals (Ticker: CRNX), a resource for investors and traders seeking the latest updates and insights on Crinetics Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Crinetics Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Crinetics Pharmaceuticals's position in the market.

Rhea-AI Summary
Radionetics Oncology, Inc. (RADN) completes $52.5 million Series A financing led by Frazier Life Sciences, 5AM Ventures, and DCVC Bio, bringing total raised to date to $82.5 million. Paul Grayson joins as CEO, bringing expertise in business strategy, oncology, and G-protein coupled receptor biology. Eric Shiozaki, Ph.D., Partner at DCVC Bio, appointed to the board of directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
management
-
Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced positive initial findings from its ongoing open-label Phase 2 carcinoid syndrome (CS) study of paltusotine, an oral, once-daily investigational compound being developed for the treatment of acromegaly and CS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.49%
Tags
-
Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. (CRNX) granted non-qualified stock options to six new non-executive employees under the 2021 Inducement Plan. The options have an exercise price of $33.27 per share and will vest over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.09%
Tags
none
Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) to participate in fireside chats at the 6th Annual Evercore ISI HealthCONx Conference and Piper Sandler 35th Annual Healthcare Conference. Details of the events and webcast accessibility provided. Contact information for arranging in-person meetings also available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
conferences
-
Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. (CRNX) Grants Stock Options to New Non-Executive Employees Under 2021 Inducement Plan
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. (CRNX) reports successful results for the PATHFNDR-1 Phase 3 study for acromegaly. Anticipates initial data from the Phase 2 study of paltusotine in carcinoid syndrome in December 2023 and topline data from the PATHFNDR-2 study in 1Q 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.62%
Tags
Rhea-AI Summary
GordonMD Global Investments LP announces joint investment in Radionetics Oncology
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
none
-
Rhea-AI Summary
Radionetics Oncology initiates Phase 1 study for 68Ga-R8760 in adrenocortical carcinoma patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
-
Rhea-AI Summary
Crinetics Pharmaceuticals grants non-qualified stock options to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
none
Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. will participate in a fireside chat and investor meetings at the Cantor Global Healthcare Conference in New York City on September 26-28, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.62%
Tags
conferences
Crinetics Pharmaceuticals Inc

Nasdaq:CRNX

CRNX Rankings

CRNX Stock Data

3.47B
64.74M
1.92%
97.19%
6.3%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
San Diego

About CRNX

neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.